Evolus Q3 revenue rises 13% on toxin and HA gel growth

What happened

Evolus said third-quarter revenue rose 13% year over year, supported by about 11% growth in toxin revenue and nearly 40% growth in injectable hyaluronic acid gel revenue. The company reported its fourth consecutive quarter of positive adjusted EBITDA and reaffirmed its 2026 revenue and adjusted gross profit margin guidance.

Confirmed

Global impact / market context

Growth across toxin and gel products can increase sales, while the fourth consecutive quarter of positive adjusted EBITDA suggests improving ability to cover operating costs. Evolus also updated its 2026 operating expense outlook, so investors will weigh product growth against planned spending and its effect on profitability.

Analyst inference

The article reports product-led growth and reaffirmed 2026 revenue and adjusted gross profit margin guidance, but does not provide a share-price reaction or detailed comparison with expectations. The updated operating expense range adds a cost measure investors can compare with future sales growth.

Analyst inference

What to watch

1. Watch whether toxin and injectable HA gel revenue continue growing, since sustained product sales would support total revenue and test whether reported demand and customer reorders persist. Analyst inference
2. Compare future results with Evolus’s reaffirmed 2026 revenue outlook and adjusted gross profit margin outlook, which indicate its sales and product-profit expectations. Confirmed
3. Track operating expenses against the updated 2026 outlook; spending rising faster than sales could limit improvement in adjusted operating results and reduce cash available. Analyst inference

Evidence

• Original source link unavailable